Market Overview

Colgate-Palmolive's Weak Sales Growth 'Will Become The Norm,' Macquarie Says In Downgrade

Share:
Colgate-Palmolive's Weak Sales Growth 'Will Become The Norm,' Macquarie Says In Downgrade
Related CL
Paws Up: The First Pets ETF Is Here
Jim Cramer Weighs In On Biogen, Colgate-Palmolive And More
Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital (Seeking Alpha)

Colgate-Palmolive Co. (NYSE: CL) reported weaker-than-expected second-quarter sales Friday and lowered its net sales growth projection.

The Analysts

Macquarie analyst Caroline Levy downgraded Colgate-Palmolive from Outperform to Neutral and lowered the price target from $74 to $65.

The Thesis

Despite CL’s EPS results, which matched consensus estimates, organic sales growth was below analysts' expectations.

This low growth was driven by increased material costs and other headwinds, accounting for a disappointing second quarter in all aspects, Levy said in the downgrade note. (See the analyst's track record here.) 

“We believe the company’s underwhelming organic sales growth in the second quarter [of 0.3 percent] will become the norm for the remainder of fiscal 2018, as the company tries to protect margins with price hikes beginning in Q3, placing even more pressure on volumes,” the analyst said. 

Productivity savings should offset higher freight costs, but commodity costs will hurt margins, Levy said. While there is value in in CL’s global brand franchises, Macquarie projects that a spike in growth is unlikely in the foreseeable future.

Cost pressures are likely to remain escalated going forward, Levy said. 

In a Friday conference call, Colgate-Palmolive CEO Ian Cook said rising commodity costs and "volatile" exchange rates have pressured Colgate's profit and loss.

" ...We have sometimes questioned if we’re responding with an appropriate sense of urgency,” Cook said.

Price Action

CL shares were down 0.3 percent at $66.46 at the close Monday. 

Related Links:

Argus: Colgate Shares Offer Investors Value

Bernstein: Colgate's Got A Target On Its Back For Activist Investors

Latest Ratings for CL

DateFirmActionFromTo
Oct 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Oct 2018ArgusMaintainsBuyBuy
Oct 2018SunTrust Robinson HumphreyDowngradesBuyHold

View More Analyst Ratings for CL
View the Latest Analyst Ratings

Posted-In: Caroline Levy MacquarieAnalyst Color Downgrades Price Target Analyst Ratings Media Best of Benzinga

 

Related Articles (CL)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ACBIKeefe Bruyette & WoodsUpgrades21.0
COTYBMO CapitalUpgrades12.0
ECCOppenheimerDowngrades0.0
VYGRRaymond JamesUpgrades0.0
ATNXJP MorganUpgrades15.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

The IPO Outlook For The Week: A Light Slate Of Tech, Real Estate

Scythian's $105M Florida Acquisition, Segra's Raise, Organigram's Record Quarter